As CAR-T comes into earlier lines and are much more accessible in countries like Germany, but also France, Spain, Italy, when we have this European meeting here, the European CAR-T meeting, we have to talk about access, because not everyone in Germany, even Germany, but even in Europe, can afford or can get CAR T-cell therapy. So we have a lot of investments into academic CAR-T products, point-of-care products, decentralized manufacturing...
As CAR-T comes into earlier lines and are much more accessible in countries like Germany, but also France, Spain, Italy, when we have this European meeting here, the European CAR-T meeting, we have to talk about access, because not everyone in Germany, even Germany, but even in Europe, can afford or can get CAR T-cell therapy. So we have a lot of investments into academic CAR-T products, point-of-care products, decentralized manufacturing. But first of all we need to state that there is inequality and inequity in Europe when it comes to CAR-T access and therapy. The other issue is about affordability because if we want to have equality we have to have affordability. Patients need the same money to invest in the same therapy in Bulgaria, in Germany, but also in Switzerland, in Poland. So we have to discuss what the next few steps should be to implement this equality. And that’s what we have to talk about here and somehow find a solution.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.